Multipotent Stem Cell Concentrate from Vascularized Adipose Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and using stem cells from adipose tissue face challenges such as low productivity, limited understanding of cell composition, and the need for large cell quantities for therapeutic effectiveness, which increases costs and restricts their use in treating various diseases.
Innovation Solution
A high-productivity process for obtaining a multipotent and immunocompatible stem cell concentrate from vascularized adipose tissue, comprising immature stem cells, mesenchymal stem cells, and pericytes, which can be used in smaller amounts for a variety of therapeutic treatments, including osteoarticular, muscular, neurological, and dermatological diseases, by optimizing cell culture and division processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If stem cells are isolated and cultivated from adipose tissue using conventional methods, then stem cells can be obtained for therapy, but the productivity of multiplication processes is low compared to the needs of therapy
Solution Approach 1:
The patent combines multiple cell types (mesenchymal stem cells, pericytes, and immature stem cells) into a single concentrate formulation. This merging of different cell populations with complementary functions achieves therapeutic effectiveness using smaller total cell quantities, thereby improving productivity efficiency without requiring large-scale cell multiplication
Solution Approach 2:
The invention creates a composite cell concentrate containing heterogeneous cell types (MSCs, pericytes, and immature stem cells) that work synergistically. This composite approach enhances therapeutic potency per cell, reducing the overall quantity needed and effectively resolving the productivity bottleneck
2Reliability
If large amounts of stem cells are used to achieve effectiveness in therapies, then therapeutic outcomes are improved, but the cost of stem cell therapy increases
Solution Approach 1:
By merging multiple cell types with different therapeutic functions into one concentrate, the patent achieves reliable therapeutic outcomes with reduced total cell numbers. The synergistic interaction between cell types enhances efficacy, allowing lower quantities to maintain or improve therapeutic reliability
3Adaptability or versatility
If stem cells are used for treating various diseases, then the range of treatable conditions expands, but the understanding of stem cell composition is limited
Solution Approach 1:
The patent applies local quality by creating disease-specific or tissue-specific cell concentrates with optimized compositions. Different concentrates are formulated with specific ratios of pericytes, MSCs, and immature stem cells tailored to the therapeutic needs of different conditions, expanding versatility while maintaining compositional precision
Solution Approach 2:
The invention utilizes parameter changes by adjusting the composition ratios and characteristics of the cell concentrate based on the target disease or tissue. This allows the same basic cell source to be adapted for multiple therapeutic applications, expanding the range of treatable conditions through controlled compositional variations
Data Source
Figure 1~3
Figure 4~6
AI summary
The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.